Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock

Key Points

• Pharvaris director Johannes Gerardus Chri Schikan sold a total of 40,000 shares in late April for about $1.21 million, including 3,830 shares on April 29 for $115,168.10; after the April 29 sale he directly owned 384,237 shares (valued at ~$11.55M at that time).
• PHVS shares fell 5.1% to $29.44 on Friday with heavy trading (512,191 shares vs. an average of 245,049), trading near its 52-week high of $31.14.
• Analyst sentiment is mixed but leans positive overall: the stock has an average rating of "Moderate Buy" (11 Buys, 2 Holds, 1 Sell) and an average price target of $42.73, while individual firms have issued both downgrades and high price targets up to $60.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Johannes Gerardus Chri Schikan sold 3,830 shares of the firm's stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10. Following the sale, the director directly owned 384,237 shares of the company's stock, valued at $11,554,006.59. The trade was a 0.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total transaction of $881,402.40.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Stock Down 5.1%

Shares of PHVS stock traded down $1.57 during mid-day trading on Friday, reaching $29.44. 512,191 shares of the company were exchanged, compared to its average volume of 245,049. Pharvaris N.V. has a fifty-two week low of $14.59 and a fifty-two week high of $31.14. The business's 50 day simple moving average is $27.62 and its 200 day simple moving average is $26.03.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). On average, equities research analysts predict that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PHVS. Wall Street Zen downgraded shares of Pharvaris from a "sell" rating to a "strong sell" rating in a research report on Monday, April 13th. Wolfe Research started coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price objective for the company. Citigroup reaffirmed a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a report on Tuesday, April 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $42.73.

Hedge Funds Weigh In On Pharvaris

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new position in Pharvaris in the fourth quarter worth $35,000. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Pharvaris in the third quarter worth $75,000. Barclays PLC acquired a new position in Pharvaris in the fourth quarter worth $77,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Pharvaris in the fourth quarter worth $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.